Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma

Jin,Minfei; Yang,Zujing; Ye,Weiping; Yu,Xiaowei; Hua,Xiaolin

doi:10.3892/ol.2015.3319

Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma

Authors:
- Minfei Jin
- Zujing Yang
- Weiping Ye
- Xiaowei Yu
- Xiaolin Hua
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China, Department of Orthopedics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 220023, P.R. China
Published online on: June 4, 2015 https://doi.org/10.3892/ol.2015.3319
Pages: 857-862

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone methyltransferase enhancer of zeste homolog 2 (EZH2) has been reported to be associated with certain malignant phenotypes in cervical cancer. However, clinicopathological parameters and clinical outcomes of EZH2 in cervical cancer, particularly in cervical squamous cell carcinoma (CSCC) remain largely unknown. The retrospective cohort comprising of 117 consecutive patients with CSCC was incorporated into a tissue microarray which also included 23 paired normal tissues. Immunohistochemical analysis was performed to evaluate the correlation between EZH2 expression and clinicopathological implications. Aberrant overexpression of EZH2 was frequently observed in CSCCs as compared with adjacent normal tissues (P=0.0005). Expression of EZH2 is associated with poor tumor differentiation grade (P=0.020) and lymphovascular invasion (P=0.012). Univariate analysis revealed that the patients with CSCC whose tumors exhibited higher EZH2 levels had inferior overall survival (OS) compared to those whose tumors expressed lower EZH2 (log rank P=0.004). In the multivariate analysis, EZH2 expression was an independent predictor of OS (hazard ratio = 1.836, 95% confidence interval: 1.090‑2.993, P=0.022). EZH2 overexpression is common in the development of CSCC and is a promising prognostic predictor for patients with CSCC.

View Figures

View References

1	Vizcaino AP, Moreno V, Bosch FX, et al: International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer. 86:429–435. 2000. View Article : Google Scholar : PubMed/NCBI
2	Koutsky L: Epidemiology of genital human papillomavirus infection. Am J Med. 102:3–8. 1997. View Article : Google Scholar : PubMed/NCBI
3	Moore DH, Blessing JA, McQuellon RP, et al: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 22:3113–3119. 2004. View Article : Google Scholar : PubMed/NCBI
4	Baylin SB and Ohm JE: Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
5	Simon JA: Transcription. Sweet silencing. Science. 325:45–46. 2009. View Article : Google Scholar : PubMed/NCBI
6	Valk-Lingbeek ME, Bruggeman SW and van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell. 118:409–418. 2004. View Article : Google Scholar : PubMed/NCBI
7	Wei Y, Chen YH, Li LY, et al: CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 13:87–94. 2011. View Article : Google Scholar : PubMed/NCBI
8	Chen S, Bohrer LR, Rai AN, et al: Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol. 12:1108–1114. 2010. View Article : Google Scholar : PubMed/NCBI
9	Viré E, Brenner C, Deplus R, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
10	Gieni RS and Hendzel MJ: Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer. Biochem Cell Biol. 87:711–746. 2009. View Article : Google Scholar : PubMed/NCBI
11	Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
12	Gong Y, Huo L, Liu P, et al: Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 117:5476–5484. 2011. View Article : Google Scholar : PubMed/NCBI
13	Cao W, Feng Z, Cui Z, et al: Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer. 118:2858–2871. 2012. View Article : Google Scholar : PubMed/NCBI
14	Cao W, Younis RH, Li J, et al: EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev Res (Phila). 4:1816–1824. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cao W, Ribeiro Rde O, Liu D, et al: EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One. 7:e52984–2012. View Article : Google Scholar : PubMed/NCBI
16	Kikuchi J, Kinoshita I, Shimizu Y, et al: Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer. 116:3015–3024. 2010. View Article : Google Scholar : PubMed/NCBI
17	Huqun, Ishikawa R, Zhang J, et al: Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer. 118:1599–1606. 2012. View Article : Google Scholar : PubMed/NCBI
18	He LR, Liu MZ, Li BK, et al: High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 127:138–147. 2010. View Article : Google Scholar : PubMed/NCBI
19	Hinz S, Weikert S, Magheli A, et al: Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol. 182:2920–2925. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al: Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 18:298–301. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hou T, Liang D, Xu L, et al: Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer. Gynecol Oncol. 130:181–187. 2013. View Article : Google Scholar : PubMed/NCBI
22	Shibata D: Mutation and epigenetic molecular clocks in cancer. Carcinogenesis. 32:123–128. 2011. View Article : Google Scholar : PubMed/NCBI
23	Valk-Lingbeek ME, Bruggeman SW and van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell. 118:409–418. 2004. View Article : Google Scholar : PubMed/NCBI
24	Zhou J, Roh JW, Bandyopadhyay S, et al: Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol. 128:344–348. 2013. View Article : Google Scholar : PubMed/NCBI
25	Li H, Bitler BG, Vathipadiekal V, et al: ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila). 5:484–491. 2012. View Article : Google Scholar : PubMed/NCBI
26	Chen SQ, Zhang HM, Li JB, et al: Analyzing simultaneous positive expression of EZH2 and P53 protein to improve predictive value in cervical squamous cell carcinoma. Int J Gynecol Cancer. 24:1653–1658. 2014. View Article : Google Scholar : PubMed/NCBI
27	Fang J, Zhang M and Li Q: Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer. Am J Med Sci. 342:198–204. 2011. View Article : Google Scholar : PubMed/NCBI
28	Breuer RH, Snijders PJ, Smit EF, et al: Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia. 6:736–743. 2004. View Article : Google Scholar : PubMed/NCBI